Background. Recurrent head and neck malignancies remain a therapeutic challenge. Tissue transfer, in addition to defect coverage and prevention of wound complications, may potentially decrease radiotoxicity. We evaluated radiation toxicity and survival outcomes of patients who underwent salvage surgery with reirradiation, comparing primary closure to flap reconstruction. Methods. Retrospective outcomes analysis of recurrent head and neck squamous cell carcinoma (HNSCC) patients treated with curative intent by salvage surgery (± flap reconstruction) and reirradiation from 1996 to 2011. Recurrent stage, reirradiation modality, chemotherapy use, and toxicities were evaluated. Results. Of 96 patients, 59 had primary closure, whereas 37 underwent flap reconstruction (26 free, 11 pedicled). Median radiation and reirradiation doses were 66 Gy and 60 Gy, respectively. Comparing nonflap and flap patients, there was no significant difference in acute mild toxicities (100 vs. 100 %, p = 1.0) or acute severe toxicities (33.9 vs. 37.8 %, p = 0.83). Nonflap patients experienced significantly greater incidence of both late mild toxicities (81.4 vs. 54.1 %, p = 0.006) and late severe toxicities (47.5 vs. 21.6 %, p = 0.02). Overall survival at 5 years was equivalent (33.1 vs. 34.7 %, p = 0.88). Free flap patients had greater delays to postoperative reirradiation and treatment package times compared with pedicled flap patients but no meaningful difference in survival outcomes.
ABSTRACT
Background. Recurrent head and neck malignancies remain a therapeutic challenge. Tissue transfer, in addition to defect coverage and prevention of wound complications, may potentially decrease radiotoxicity. We evaluated radiation toxicity and survival outcomes of patients who underwent salvage surgery with reirradiation, comparing primary closure to flap reconstruction. Methods. Retrospective outcomes analysis of recurrent head and neck squamous cell carcinoma (HNSCC) patients treated with curative intent by salvage surgery (± flap reconstruction) and reirradiation from 1996 to 2011. Recurrent stage, reirradiation modality, chemotherapy use, and toxicities were evaluated. Results. Of 96 patients, 59 had primary closure, whereas 37 underwent flap reconstruction (26 free, 11 pedicled). Median radiation and reirradiation doses were 66 Gy and 60 Gy, respectively. Comparing nonflap and flap patients, there was no significant difference in acute mild toxicities (100 vs. 100 %, p = 1.0) or acute severe toxicities (33.9 vs. 37.8 %, p = 0.83). Nonflap patients experienced significantly greater incidence of both late mild toxicities (81.4 vs. 54.1 %, p = 0.006) and late severe toxicities (47.5 vs. 21.6 %, p = 0.02). Overall survival at 5 years was equivalent (33.1 vs. 34.7 %, p = 0.88). Free flap patients had greater delays to postoperative reirradiation and treatment package times compared with pedicled flap patients but no meaningful difference in survival outcomes.
Conclusions. Vascularized tissue potentially helps offset late toxicities associated with a second radiation course in recurrent head and neck cancer patients. In these selected patients, flap coverage may confer functional benefits and improve the long-term radiotoxicity profile.
Salvage treatment of recurrent, previously irradiated head and neck squamous cell carcinoma (HNSCC) continues to pose a considerable challenge. For resectable disease, salvage surgery offers superior overall survival and locoregional control compared with chemotherapy or reirradiation.
1,2 However, in many cases patients are still at high risk for further recurrence after salvage surgery alone, warranting a second course of radiation.
Reirradiation with or without concurrent chemotherapy has shown promise in conferring locoregional control and survival benefits in head and neck cancer patients with resectable disease. 3, 4 It nonetheless poses the threat of escalated toxicity in previously damaged tissues, and effects may be magnified in postsurgical patients with increased risk of wound complications. 5 Flap reconstruction, although lengthy and complicated, reduces the risk of wound breakdown and fistula formation in poorly vascularized, previously irradiated tissue. Prior studies suggest that the addition of flaps is a robust means of wound closure, but it is unclear whether the interposition of well-vascularized, un-radiated tissue affords protection from the deleterious effects of reirradiation. 6 We examined the incidence of reirradiation toxicities after salvage surgery with and without flap reconstruction.
METHODS
Retrospective analysis of recurrent HNSCC patients undergoing reirradiation at Memorial Sloan Kettering Cancer Center (MSKCC) from October 1996 to April 2011 was performed. Eligible patients included those with recurrent or second primary HNSCC who had previously received a full course of head and neck radiation therapy (RT), underwent salvage surgery with curative intent, and had adjuvant reirradiation due to sufficiently high risk of locoregional recurrence based on surgical pathology. Highrisk features included close or positive margins, invasion of local structures, perineural or vascular invasion, multiple positive lymph nodes, and extracapsular spread. Staging of the recurrent tumor was determined based on American Joint Committee on Cancer, 7th edition. 7 To avoid accounting for symptoms resulting from recurrent disease or additional therapy, adverse events after reirradiation were censored on disease progression.
Special attention was paid to the reirradiation toxicity outcomes in patients who underwent primary closure of their surgical sites versus those who received flap reconstruction (pedicled or free flaps). In all cases, the reirradiation fields coincided with or overlapped previous RT fields and included the flap if present. Acute toxicities were defined as less than 90 days from completion of reirradiation, with late toxicities as greater than 90 days. Toxicities were assessed by patient-reported outcomes via questionnaire, using 1995 guidelines published by the RT Oncology Group (RTOG) and European Organization for Research and Treatment of Cancer (EORTC) ( Table 1) . 8 Retrospective review of records was used to confirm objective longitudinal sequelae. Those that existed before reirradiation, such as PEG dependence and tracheostomy dependence, were excluded from the analysis. Treatment package time was defined as the interval between the date of salvage surgery and the end of reirradiation. 9 Exclusion criteria consisted of patients with distant metastatic disease who did not complete the majority of their reirradiation course, who underwent RT for palliative intent, who received RT for noncancers, and who received radiation in non-overlapping sites. Associations between variables and endpoints were assessed with Fisher exact test or v 2 with Yates correction. Disease-free survival (DFS) and overall survival (OS) were estimated using the Kaplan-Meier method and analyzed using the log-rank test. All p values were two-sided, with significance set at p \ 0.05. Statistical analyses were performed using SPSS Version 20 (Chicago, IL).
RESULTS

Patient Demographics
A total of 96 patients were included in the study; 59 patients underwent salvage surgery with primary closure, whereas 37 patients required reconstruction with tissue flaps at the time of salvage surgery (11 pedicled flaps, 26 microvascular free flaps; Fig. 1 ). Excluded patients comprised those with distant metastases prior to reirradiation (n = 38), cutaneous malignancy diagnoses (n = 19), lack of radiation site overlap (n = 16), lack of primary or recurrent cancer diagnosis (n = 4), and subtherapeutic reirradiation dose (n = 2). Collectively, median age was 62.0 years (95 % confidence interval [CI] 59.8-64.2), and 83.3 % had recurrent advanced stage (rStage 3-4) disease. The neck, oral cavity, oropharynx, and larynx were the most common sites of recurrence. In terms of recurrences prior to salvage surgery and reirradiation, 36.5 % were local, 30.2 % were regional, 20.8 % were locoregional, and 12.8 % were second primaries. The cohorts were well-matched in terms of patient and tumor characteristics, both when comparing primary closure versus flap (Table 2) as well as comparing pedicled flap versus free flap (Table 3) .
Radiation Characteristics
The median initial radiation dose was 66.0 Gy (95 % CI 64.8-67.2). The median reirradiation dose was 60.0 Gy (95 % CI 57.8-62.2). The majority of patients (72.9 %) had intensity-modulated RT (IMRT) for their reirradiation.
Before their full-course reirradiation, three patients received intraoperative RT and two received a brachytherapy boost. One-half (50.0 %) of patients received concurrent chemotherapy with reirradiation. The median time interval between the date of salvage surgery and initiating reirradiation was 8 weeks. Median follow-up for surviving patients after reirradiation was 50.6 months (95 % CI, 35.9-65.7). Median survival time after reirradiation was 19.5 months (95 % CI 12.7-26.3).
Nonflap Versus Flap Patients
The distribution of cancer histology, advanced stage (of initial and recurrent cancers), and DFI was not significantly different between groups. Reirradiation dosages, IMRT usage, and concomitant chemotherapy usage were similar. In the nonflap group, more laryngeal cancer cases (39.0 vs. 21.6 %, p = 0.03) and fewer oral cavity cases (22.0 vs. 43.2 %, p = 0.04) were observed. There were more local recurrences in the flap cohort (62.2 vs. 20.3 %, p \ 0.001); conversely, there were more regional recurrences in the nonflap cohort (40.7 vs. 13.5 %, p = 0.006). Recurrence rate and overall survival were not significantly different between groups. For nonflap versus flap cohorts, 3-year OS was 38.2 vs. 36.8 % (p = 0.53), whereas 5-year OS was 33.1 vs. 34.7 % (p = 0.88). Flap patients did not demonstrate a higher rate or earlier rate of local re-recurrence compared with nonflap patients. The incidence of acute mild toxic symptoms from reirradiation was 100 % in both cohorts, with xerostomia, mucositis, and dermatitis being the most common side effects (Table 4 ). There was no significant difference in the incidence of acute severe toxicity after reirradiation (33.9 % in the nonflap group vs. 37.8 % in the flap group, p = 0.83). Nonflap patients were significantly more likely to experience mild late toxicities (81.4 % of nonflaps vs. 54.1 % of flaps, p = 0.006), as well as severe late toxicities (47.5 vs. 21.6 %, p = 0.02).
In terms of major sequelae after surgery and reirradiation, 18.6 % of nonflap and 18.9 % of flap patients developed wound dehiscence (p = 1.00). Rates of osteoradionecrosis (8.4 vs. 5.4 %, p = 0.70) and fistula formation (8.4 vs. 10.8 %, p = 0.73) were similar between groups. Carotid blowout was noted in one patient (nonflap group), whereas treatment-related death occurred in one patient (flap group). There were no cases of flap breakdown or failure. Long-term incidence of PEG dependence due to reirradiation was similar between nonflap and flap cohorts (18.6 vs. 18.9 %, p = 1.00), as was tracheostomy dependence (20.3 vs. 21.6 %, p = 1.00). Despite the added recovery time presumably associated with flaps, there was no significant difference in time interval between salvage surgery and reirradiation (9.4 vs. 8.7 weeks, p = 0.82), the median salvage treatment package time (96.0 vs. 103.0 days, p = 0.88), or the number that failed to complete their reirradiation course (3.4 vs. 13.5 %, p = 0.10).
Pedicled Flap Versus Free Flap Patients
On subset analysis between pedicled and free flaps, there were more laryngeal cancer patients in the pedicled flap group (45.5 vs. 11.5 %, p = 0.04). Regional recurrences were more likely to be found in the pedicled flap cohort (45.5 vs. 0 %, p = 0.001), but not so if combined with locoregional recurrences. Pedicled flap cases had significantly shorter postoperative intervals to begin reirradiation (8.1 vs. 8.9 weeks, p = 0.05), as well as overall treatment package time (99.0 vs. 106.5 days, p = 0.04). However, there were no substantial differences in total radiation PEG percutaneous endoscopic gastrostomy, DVT deep vein thrombosis * Excludes patients who were PEG-dependent or tracheostomy-dependent before reirradiation doses or toxicity (Table 3) , in functional sequelae (Table 4) , median survival, or overall survival.
DISCUSSION
The impact of flap reconstruction on outcomes in the postoperative reirradiation scenario is unclear. Wound closure with nonradiated tissue could be expected to better withstand adjuvant reirradiation than previously irradiated tissue at the surgical site. However, flaps may require longer postoperative healing periods, delaying reirradiation and potentially compromising outcome. In this study, the application of nonradiated tissue via flaps during salvage surgery was associated with significantly fewer mild (54.1 vs. 81.4 %, p = 0.006) and severe long-term toxicities (21.6 vs. 47.5 %, p = 0.02) following postoperative reirradiation. The cohorts were largely matched in terms of stage, suggesting that one group did not necessarily harbor more aggressive disease or sicker patients. Other indicators, such as reirradiation dose and proportion of patients receiving concomitant chemotherapy, were similar.
There are several plausible mechanisms by which flaps could be hypothesized to lead to decreased long-term toxicity. Radiation has well-characterized deleterious effects on tissue vascularization. 10, 11 By delivering unirradiated, vascularized tissue to the site of reirradiation, we might expect flaps to be less compromised by radiation vasculopathy than previously radiated tissue. Flaps also provide more bulk and protection to the surrounding tissue during reirradiation than the native tissue, which can become atrophic and fibrotic following radiotherapy. These advantages of flap reconstruction are notwithstanding its fundamental importance in protecting radiated fields from wound breakdown in large defects and in facilitating reirradiation delivery where affected skin must be sacrificed.
Notably, our results extend previous reports from other groups. For example, prior retrospective series examined flaps in the postoperative reirradiation setting but did not demonstrate differences in radiotoxicity. [12] [13] [14] This may have been due to study design, small sample size, inclusion of noncurative or nonsurgical patients, or institutional selection criteria for salvage. In addition, a relatively high percentage of patients in our study received reirradiation via IMRT (72.9 %). IMRT enables precise dose distribution, limits injury to adjacent organs, and consequently may improve reirradiation outcomes. 15, 16 The narrower treatment fields reduce side effects in a previously radiated setting and may have helped to allow the beneficial effect of flaps on late reirradiation toxicities to become apparent.
Multiple studies have suggested that reirradiation with chemotherapy may be beneficial, but significant concerns persist regarding toxicity. For example, both RTOG 96-10 and RTOG 99-11 prospectively demonstrated that reirradiation with concomitant chemotherapy is feasible, with survival rates superior to historical trials of chemotherapy alone, but 8 % of patients experienced treatment-related deaths, and 32 % enrolled in RTOG 99-11 experienced grade 4-5 toxicity. 17, 18 Additionally, Janot et al. found that postoperative reirradiation with concomitant chemotherapy resulted in improved progression-free survival following surgical resection in previously irradiated fields. However, 8 % of patients randomized to chemo-reirradiation experienced treatmentrelated death and 39 % of those surviving 24 months had late grade 3-4 toxicity. 19 Thus, the considerable side effects reported poses stiff barriers to treatment, even for patients with few other options. If flap reconstruction can offset adverse treatment sequelae, its use may meaningfully improve quality of life and favorably tilt the therapeutic ratio. This strategy may address the reluctance of clinicians to apply a second therapeutic course of radiation.
Even if flaps were able to improve the radiotoxicity profile, their use may be difficult to justify if they markedly delay treatment. Compared with pedicled flap patients, those with free flaps had a longer delay to start postoperative reirradiation (8.1 vs. 8.9 weeks, p = 0.05), as well as a longer median treatment package time (99.0 vs. 106.5 days, p = 0.04). These prolonged intervals are likely due to longer healing times associated with microvascular reconstruction. Ang et al. suggested that prolonged treatment intervals led to lower locoregional control and survival. 20 Similarly, Rosenthal et al. identified that a total treatment time of greater than 100 days was associated with poorer survival. 9 Such studies did not examine the reirradiation population, and in our study free flaps did not worsen survival. Nonetheless, the consequences of potential delays are worthy of consideration in determining management.
There are multiple caveats to this analysis, including its retrospective nature, with associated selection and referral bias. Flap coverage may not be necessary in all settings or the only option in others. The heterogeneity of sites and the flaps placed also may impact the study's generalizability. For instance, larynx cancer patients tend to have improved survival outcomes compared with other sites and comprised a higher percentage of the nonflap group. 2, 21 Finally, although we have shown no differences in stage, treatment dose, or treatment interval, flap patients may a priori harbor more extensive lesions, defects, and tissue compromise not completely captured by staging or treatment metrics. In this context, the mitigated toxicities found in flap patients are perhaps even more noteworthy. S856 A. S. Ho et al.
